Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Clinical therapeutics - 1 Oct 2012

Chang Mei H, Gordon Lori A, Fung Horatio B

Abstract excerpt

BACKGROUND: Boceprevir is a protease inhibitor indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in combination with peginterferon and ribavirin for treatment-naive patients and those who previously failed to improve with interferon and ribavirin treatment. OBJECTIVE: This article provides an overview of the mechanism of action, pharmacologic and pharmacokinetic properties,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Polyethylene Glycols
Share to Proline
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Protease Inhibitors

Share to Ribavirin

Source

Identifiers

PMID: 22975763
DOI: 10.1016/j.clinthera.2012.08.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Boceprevir: a protease inhibitor for the treatment of hepatitis C.PMID 22975763Read ↗

Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.Semantic proximity Read ↗

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.Semantic proximity Read ↗

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

[New agents for the treatment of hepatitis C].Semantic proximity Read ↗

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Semantic proximity Read ↗

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.Semantic proximity Read ↗

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.